Show simple item record

dc.contributor.authorPérez-Breva, Lina
dc.contributor.authorVillanueva, Rafael J
dc.contributor.authorVillanueva-Oller, Javier
dc.contributor.authorAcedo, Luis
dc.contributor.authorSantonja, Francisco
dc.contributor.authorMoraño, José A
dc.contributor.authorAbad, Raquel 
dc.contributor.authorVazquez-Moreno, Julio Alberto 
dc.contributor.authorDíez-Domingo, Javier
dc.identifier.citationBMC Infect Dis. 2014 May 21;14:280.es_ES
dc.description.abstractBACKGROUND: Meningococcal C (MenC) conjugate vaccines have controlled invasive diseases associated with this serogroup in countries where they are included in National Immunization Programs and also in an extensive catch-up program involving subjects up to 20 years of age. Catch-up was important, not only because it prevented disease in adolescents and young adults at risk, but also because it decreased transmission of the bacteria, since it was in this age group where the organism was circulating. Our objective is to develop a new vaccination schedule to achieve maximum seroprotection in these groups. METHODS: A recent study has provided detailed age-structured information on the seroprotection levels against MenC in Valencia (Spain), where vaccination is routinely scheduled at 2 months and 6 months, with a booster dose at 18 months of age. A complementary catch-up campaign was also carried out in n for children from 12 months to 19 years of age. Statistical analyses of these data have provided an accurate picture on the evolution of seroprotection in the last few years. RESULTS: An agent-based model has been developed to study the future evolution of the seroprotection histogram. We have shown that the optimum strategy for achieving high protection levels in all infants, toddlers and adolescents is a change to a 2 months, 12 months and 12 years of age vaccination pattern. If the new schedule were implemented in January 2014, high-risk subjects between 15-19 years of age would have very low seroprotection for the next 6 years, thereby threatening the program. CONCLUSIONS: High protection levels and a low incidence of meningococcal C disease can be achieved in the future by means of a cost-free change in vaccination program. However, we recommend a new catch-up program simultaneous to the change in regular vaccination program.es_ES
dc.description.sponsorshipThis paper has been supported by grant FIS PI-10/01433 from the Instituto de Salud Carlos III, and grant PAID-06-11 ref: 2087 from the Universitat Politècnica de València. An agreement between CSISP-FISABIO and Baxter Laboratories for epidemiological studies of meningococcal C disease is also acknowledged.es_ES
dc.publisherBioMed Central (BMC) es_ES
dc.subjectMeningococcal C conjugate vaccineses_ES
dc.subjectSeroprotection studyes_ES
dc.subjectAgent-based modellinges_ES
dc.subjectVaccination programses_ES
dc.subject.meshAdolescent es_ES
dc.subject.meshAdult es_ES
dc.subject.meshChild es_ES
dc.subject.meshChild, Preschool es_ES
dc.subject.meshFemale es_ES
dc.subject.meshHumans es_ES
dc.subject.meshMale es_ES
dc.subject.meshMeningococcal Infections es_ES
dc.subject.meshMeningococcal Vaccines es_ES
dc.subject.meshMiddle Aged es_ES
dc.subject.meshSpain es_ES
dc.subject.meshVaccination es_ES
dc.subject.meshYoung Adult es_ES
dc.subject.meshImmunization Programs es_ES
dc.titleOptimizing strategies for meningococcal C disease vaccination in Valencia (Spain)es_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.contributor.funderInstituto de Salud Carlos III 
dc.contributor.funderUniversity of Valencia (España) 
dc.identifier.journalBMC infectious diseaseses_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.rights.accessRightsopen accesses_ES

Files in this item

Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional